Leaderboards/Tuberous Sclerosis Complex Research

Tuberous Sclerosis Complex Research

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Nicola Alesi
Brigham and Women's Hospital
2
Oliver L. Eichmüller
Institute of Molecular Biotechnology
3
Paul G. Kemps
Leiden University Medical Center
4
Jingchao Yang
Sichuan University
5
Christine Chin‐jung Hsieh
Taipei Medical University
6
Chiara Di Malta
Federico II University Hospital
7
Tyrone DeSpenza
Duke University Hospital
8
H. Mytrang
Memorial Sloan Kettering Cancer Center
9
Xiaojuan Chao
University of Kansas Medical Center
10
Nassim Homayun Sepehr
de Duve Institute

Papers

1
TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex
Nature Communications|2024
45 cit.
2
Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms
Histopathology|2024
17 cit.
3
Recurrent <i>CLTC</i>::<i>SYK</i> fusions and <i>CSF1R</i> mutations in juvenile xanthogranuloma of soft tissue
Blood|2024
14 cit.
4
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
Blood Neoplasia|2024
12 cit.
5
Publication in Proceedings of the National Academy of Sciences (2024) [11 citations, W4399999825]
Proceedings of the National Academy of Sciences|2024
11 cit.
6
Recurrent <i>ETV3</i>::<i>NCOA2</i> fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis
Blood Advances|2024
11 cit.
7
Publication in Nature Neuroscience (2025) [10 citations, W4407884145]
Nature Neuroscience|2025
10 cit.
8
Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis
Blood Cancer Journal|2026
1 cit.
9
Publication in Neurosurgery (2024) [W4392870584]
Neurosurgery|2024
0 cit.
10
Publication in EJC Paediatric Oncology (2026) [W7128908791]
EJC Paediatric Oncology|2026
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Yan Tang
Brigham and Women's Hospital
2
Helen S. Bateup
University of California, Berkeley
3
Angela D. Motter
National Comprehensive Cancer Network
4
Lata Vadlamudi
The University of Queensland
5
Nicola M. Tomas
Universität Hamburg
6
Ruth Schöpper
Unknown
7
Nina S. Corsini
Institute of Molecular Biotechnology
8
Hatem Abou–Ouf
University of Calgary
9
Christine A. Pratilas
Johns Hopkins University
10
Yunjie Li
The Affiliated Yongchuan Hospital of Chongqing Medical University

Papers

1
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
655 cit.
2
The classical pathway triggers pathogenic complement activation in membranous nephropathy
Nature Communications|2023
97 cit.
3
Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment
Nature Communications|2022
61 cit.
4
An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells
Kidney International|2024
45 cit.
5
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
Oncogene|2022
41 cit.
6
Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex
Nature Communications|2022
39 cit.
7
Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice
Kidney International|2022
35 cit.
8
Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2
eLife|2022
29 cit.
9
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors
Science Advances|2023
27 cit.
10
Passive transfer of patient-derived anti-nephrin autoantibodies causes a podocytopathy with minimal change lesions
Journal of Clinical Investigation|2025
26 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
David J. Kwiatkowski
Brigham and Women's Hospital
2
Kun‐Liang Guan
Westlake University
3
Elizabeth P. Henske
Brigham and Women's Hospital
4
David Neal Franz
Cincinnati Children's Hospital Medical Center
5
Elizabeth A. Thiele
Massachusetts General Hospital
6
Joel Moss
National Heart Lung and Blood Institute
7
Pier Paolo Pandolfi
University of Turin
8
John Blenis
Cornell University
9
Brendan D. Manning
Cancer Research Center
10
Mustafa Şahin
Boston Children's Hospital

Papers

1
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Cell|2011
7.7k cit.
2
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Nature Cell Biology|2011
7k cit.
3
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Cell|2003
3.9k cit.
4
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control
Genes & Development|2007
3.2k cit.
5
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Nature Cell Biology|2002
3.1k cit.
6
TEAD mediates YAP-dependent gene induction and growth control
Genes & Development|2008
2.5k cit.
7
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
Nature|2010
2.4k cit.
8
Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
Molecular Cell|2010
2k cit.
9
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Nature|2005
2k cit.
10
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Genes & Development|2003
1.9k cit.

Reagents for Tuberous Sclerosis Complex Research

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling Technology

FastScan™ Total TBK1/NAK ELISA Kit

Cited in 12 papers
#15816$67,830,490
View Evidence →
Cell Signaling TechnologyEvidence 65

Acetyl-alpha-Tubulin (Lys40) (D20G3) Rabbit Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

Cited in 12 papers
#35652$187,500
View Evidence →
Cell Signaling Technology

RHAMM/CD168 (E7S4Y) Rabbit Monoclonal Antibody (BSA and Azide Free)

Cited in 11 papers
#35364$865
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Phospho-WIPI2 (Ser413) Antibody

Cited in 19 papers
#13571$362
View Evidence →
Cell Signaling TechnologyEvidence 66

Phospho-Histone H3 (Thr3) (D5G1I) Rabbit Monoclonal Antibody

Cited in 17 papers
#13576$176,415
View Evidence →
Cell Signaling TechnologyEvidence 66

Bid (3C5) Mouse Monoclonal Antibody

Cited in 13 papers
#8762$158,348
View Evidence →